247 related articles for article (PubMed ID: 36861174)
1. Potential value of efficacy prediction and treatment of natural killer cells in extensive stage small cell lung cancer.
Cui Y; Zhao P; Cheng Y; Ren X
Thorac Cancer; 2023 Apr; 14(10):864-872. PubMed ID: 36861174
[TBL] [Abstract][Full Text] [Related]
2. Predictive biomarkers for immunotherapy response in extensive-stage SCLC.
Zhu L; Qin J
J Cancer Res Clin Oncol; 2024 Jan; 150(1):22. PubMed ID: 38245636
[TBL] [Abstract][Full Text] [Related]
3. Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients.
Lorenzi M; Resi MV; Bonanno L; Frega S; Dal Maso A; Ferro A; Guarneri V; Pasello G
Front Immunol; 2024; 15():1308109. PubMed ID: 38348046
[TBL] [Abstract][Full Text] [Related]
4. [Research Progress of Immunotherapy and Prognostic Markers in Small Cell Lung Cancer].
Wang Q; Peng W; Jiang M; Wu L
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):182-188. PubMed ID: 32102135
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy.
Tian Y; Ma J; Jing X; Zhai X; Li Y; Guo Z; Yu J; Zhu H
Cancer Lett; 2022 Aug; 541():215719. PubMed ID: 35597478
[TBL] [Abstract][Full Text] [Related]
6. An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC.
Fousek K; Horn LA; Qin H; Dahut M; Iida M; Yacubovich D; Hamilton DH; Thomas A; Schlom J; Palena C
J Thorac Oncol; 2023 Mar; 18(3):350-368. PubMed ID: 36410696
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer.
Choi MG; Kim YJ; Lee JC; Rho JK; Choi CM
Thorac Cancer; 2020 Nov; 11(11):3337-3345. PubMed ID: 33017518
[TBL] [Abstract][Full Text] [Related]
9. Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.
Ding X; Cao H; Chen X; Jin H; Liu Z; Wang G; Cai L; Li D; Niu C; Tian H; Yang L; Zhao Y; Li W; Cui J
J Transl Med; 2015 May; 13():158. PubMed ID: 25968637
[TBL] [Abstract][Full Text] [Related]
10. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects.
Demedts IK; Vermaelen KY; van Meerbeeck JP
Eur Respir J; 2010 Jan; 35(1):202-15. PubMed ID: 20044461
[TBL] [Abstract][Full Text] [Related]
11. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review).
Zeng Y; Lv X; Du J
Oncol Rep; 2021 Nov; 46(5):. PubMed ID: 34498710
[TBL] [Abstract][Full Text] [Related]
13. Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer.
Russell É; Conroy MJ; Barr MP
Cells; 2022 Feb; 11(4):. PubMed ID: 35203256
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy in combination with cytokine-induced killer cell transfusion: An effective therapeutic option for patients with extensive stage small cell lung cancer.
Huang J; Kan Q; Lan ; Zhao X; Zhang Z; Yang S; Li H; Wang L; Xu L; Cheng Z; Zhang Y
Int Immunopharmacol; 2017 May; 46():170-177. PubMed ID: 28292730
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
[TBL] [Abstract][Full Text] [Related]
16. Peripheral NK cells identified as the predictor of response in extensive-stage small cell lung cancer patients treated with first-line immunotherapy plus chemotherapy.
Cui Y; Chen Y; Zhao P; Li S; Cheng Y; Ren X
Clin Transl Oncol; 2024 Apr; ():. PubMed ID: 38662170
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment.
Bianco A; D'Agnano V; Matera MG; Della Gravara L; Perrotta F; Rocco D
Expert Rev Respir Med; 2021 Nov; 15(11):1415-1425. PubMed ID: 34374626
[No Abstract] [Full Text] [Related]
18. Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy.
Li T; Qiao T
Semin Cancer Biol; 2022 Nov; 86(Pt 2):117-125. PubMed ID: 36183998
[TBL] [Abstract][Full Text] [Related]
19. Harnessing Natural Killer Immunity in Metastatic SCLC.
Best SA; Hess JB; Souza-Fonseca-Guimaraes F; Cursons J; Kersbergen A; Dong X; Rautela J; Hyslop SR; Ritchie ME; Davis MJ; Leong TL; Irving L; Steinfort D; Huntington ND; Sutherland KD
J Thorac Oncol; 2020 Sep; 15(9):1507-1521. PubMed ID: 32470639
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
Liu X; Xing H; Zhang H; Liu H; Chen J
Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
